UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FormFORM 8-K

CurrentCURRENT ReportREPORT

Pursuant to Section 13 orOR 15(d) of
The the Securities Exchange Act of 1934

Date of Report:(Date Novemberof 4earliest event reported) September 1, 20022003

TekronTEKRON, IncINC.
(Exact name of smallregistrant business issuer as specified in its charter)

Commission File Number: 000-29493

Delaware 0-29493 51-0395658
(State ofor incorporation) (other jurisdiction Commission File IRS Employer
of ID Numberincorporation) Number Identification No.

530 VoyagerS. CourtFederal South,Highway Etobicoke,Deerfield OntarioBeech, CanadaFL M9W 5M733441
(Address of principal executive offices)

(519Zip/Postal Code)

Registrant's telephone number: 519-661-0609

N/A
(Issuer'sFormer telephonename numberor former address, if changed since last report)

ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE
Item
Dr. 4James Insell has been appointed as CEO and Chief Scientic Officer. ChangesHis
qualifications are outlined in Registrant'sa Certifyingrecent Accountantpress release.

On Mr. OctoberMarvin 28,Winick 2002,has been appointed as CFO of the Company's. BoardHe is a
Canadian accountant with several years of Directorspublic notifiedcompany experience.

The Company has also appointed the certifiedfollowing legal firms as counsel.
public
In accountingCanada firm- ofCarlyle Peterson, Gordon Peterson and Phil King

In the United States - Lawrence S. WHartman

ITEM 7. Hatfield,EXHIBITS

Press CPArelease of DallasSeptember 8, Texas2003 (SWHCPA)incorporated by reference, a copy of
which is attached hereto.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Company'Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Dated: September 9, 2003 TEKRON, INC.

By: s/s independentLUIGI auditorBRUN
------------------------------
Luigi Brun
President

Press Release Source: Tekron, thatInc.

Tekron, theyInc. wereAnnounces changingthe auditorsAppointment of Dr. James P. Insell as CEO, and
Chief theScientific servicesOfficer Monday September 8, 1:18 pm ET
of
FORT SWHCPALAUDERDALE, wouldFla., noSeptember longer8, be2003 required(PRIMEZONE) -- Tekron, Inc. (OTC
BB:TKRN.OB - News) announces that Luigi Brun, Chairman and President is pleased
Theto Companyappoint confirmedDr. James Insell as CEO and Chief Scientific Officer for the
Corporation.

Dr. dismissalInsell, 55, has served as President and CEO of SWHCPAMicrobe onCorporation Octobera
publicly 28traded environmental biotechnology for twelve years as well as
President of J.P. Insell & Associates, 2002scientists and engineers for the past
five years. TheHe Companyconsulted for the investment banking community, biopharma venture
hascapitalists, furnishedand SWHCPAa withgroup of high net-worth investors in Europe providing
scientific audits, engineering assessments and corporate due diligence. Dr.
Insell's career began as a copyprofessor of microbiology at UWO in Canada.
Subsequently, he founded a biotech company based on his discovery of microbial
ontogenetic evolution. For the draftnext eight years he developed and patented
designer bacteria for biopesticides and toxic waste degradation. For several
years, he worked in the biotech community in San Diego and at the University of
California, thisSan FormDiego 8as consulting associate director of science and
engineering. Currently, due to his knowledge of and experience with anthrax, he
has provided lectures and protocols for counter-Kbioterrorism to large automotive
corporations and financial institutions.

Luigi TheBrun, CompanyChairman and President of Tekron, said "I am extremely pleased
that Dr. Insell has demonstrated his confidence by joining and heading up the
requestedteam SWHCPAat Tekron. I look forward to providehis ascientific lettercontribution addressedand tothe technology
he has developed over the SECpast statingtwo thatdecades."

Dr. itInsell agreesstated, "I am excited about joining Tekron at this very exciting
withand opportunistic point in the statementsCompany's history. I am confident that we can
move our technology forward rapidly in the immediatelybest precedinginterests paragraphof the shareholders."

NoAbout accountant'sDr. reportInsell

Dr. onInsell received his B.Sc. in engineering physics from the financialUniversity statementsof
Waterloo in 1972. His scientific training broadened as he took positions at The
Hospital for eitherSick Children, Sunnybrook Hospital, Toronto, Ontario and the
University of Toronto, Department of Surgery studying the pastultrastructure twoof
(2)hyperacute yearsrejection, containedhuman anfetal adverselung opiniondevelopment orand aextracorporal disclaimerrenal
viability in the laboratories of opinionDr. orMartin wasBarkin, Dr. Cohen and Dr. G. A
qualifiedTaylor. orHe modifiedpursued ashis toelectron uncertaintymicroscopic interests studying the genetics,
ultrastructure auditand scopephysiology orof accountingpredacious principles,fungi receiving his M. Sc. in
exceptmicrobiology forin a1975 goingfrom concernthe opinionUniversity expressingof substantialWaterloo. doubtHis aboutelucidation of the
abilitynovel biophysics of thethese Companyfascinating tomicroorganisms continuewas asfeatured aby goingthe
prestigious concernjournal New Scientist. He continued his studies of the molecular
genetics and biochemistry of pathogenic sporulating bacilli, Bacillus
Duringthuringiensis theand Company'sBacillus twoanthracis mostin recentthe fiscallaboratories yearsof (endedDr. MarchPhil 31Fitz-James,
Department 2002of Bacteriology and Immunology at the University of Western Ontario
2001)and subsequently earned his Ph.D in bacteriology and immunology from Marchthe 31,School
of 2002Medicine in 1982. His studies led to an understanding of the dateorigin of thisthe
pathogenicity Reportof sporulating bacilli and their evolution. He undertook his
postdoctoral training studying the ultrastructure, therephysiology wereand nobiochemistry
disagreementsof withpsychrophilic SWHCPAand onmesophilic anypathogenic matterfungi. Dr. Insell took a faculty
position in the Department of accountingLife principlesSciences, orpursuing practiceshis research interests in
molecular evolution. In1984, Dr. Insell took his discovery of microbial
financialontogenetic disclosureevolution and founded a biotechnology company commercializing this
finding. For the next eight years, orhe auditingdeveloped scopeand orpatented procedurebacteria that
degrade toxic waste as well as developed novel strains of the insecticidal
bacteria Bacillus thuringiensis and Bacillus laterosporus and the renown human
pathogen Bacillus anthracis (anthrax). Dr. Insell took the first biotech company
public in Canada. Dr. Insell was featured in the Canadian Business Magazine as
Thewell Companyas hasbeing notnominated appointedfor the highly prestigious Ernest Manning leading
Canadian scientist award in 1986. From 1996 to 1998, Dr. Insell resided in San
Diego and became actively involved in it's biotech community, culminating in
becoming a replacementconsulting independentbiotechnology auditorassociate asdirector in engineering and
science at the University of California, San Diego. Before returning to Canada,
Dr. Insell liaised with state and federal legislators, sat on the dateBiocom
employment taskforce, working with many of thisthe filingover three hundred and willfifty
biotechnology filecompanies thein requisiteSan FormDiego 8-Kand contributed to announcethe suchbiotechnology
curriculum appointmentdevelopment at UCSD. He originated and developed several new courses
whenat applicableUCSD in design of clinical trials, FDA approval procedures, GLP and GMP. Dr.
Insell has authored over ten peered reviewed scientific publications, two
patents and over fifty scientific reports and engineering assessments. For the
2past five years, Dr Insell has been president of J.P Insell & Associates,
consulting scientists and engineers, undertaking scientific audits and
engineering assessments for investment banking and biopharma venture
capitalists. As an environmental engineer as well as a bacteriologist, Dr.
ItemInsell 7has designed and implemented numerous novel treatment systems and site
remediations and has been involved in the development of a treatment for herpes,
atherosclerosis and a cure for psoriasis. Financial StatementsMost recently, Dr. Insell has been
retained by large automotive corporations and Exhibitsfinancial institutions to provide
consulting and laboratory services for the identification and countermeasure
response to germ warfare agents and the response to other unidentified
bioharzardous materials (cRUM) Exhibits. Dr. Insell has developed bioharzard response

Exhibitprotocols Noand designed an emergency responder biohazard kit (equipment) for RUM. Description
Dr Insell teaches these protocols to the medical staff and emergency response
16personnel in the automotive industry.1 Letter regardingDr. changeInsell inlectures certifyingon accountantanthrax, tularemia,
plague, botulinum, ricin, smallpox and other viral infections such as West Nile
virus, SARS, bovine spongiformy encephalitis (mad cows disease) and their
corporate response.
SIGNATURES
About Tekron:
Pursuant
Tekron Inc. is a holding company acquiring interests in high technology,
medical and environmental biotechnology companies. This information contains
certain forward-looking statements and information relating to the requirementsCompany that
are based on the beliefs of the SecuritiesCompany Exchangeor Actmanagement ofas 1934well as assumptions
made by and information currently available to the Company or management. When
used in this document, the words "anticipate," "believe," "estimate," "expect"
Registrantand has"intend" dulyand causedsimilar thisexpressions, Reportas they relate to bethe signedCompany onor its
management, behalfare byintended the
undersignedto thereuntoidentify dulyforward-looking authorizedstatements. Such statements
reflect the current view of the Company regarding future events and are subject
Tekronto certain risks, Incuncertainties and assumptions, including the risks and
uncertainties noted. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
Date:may Novembervary 4materially from those described herein as anticipated, 2002 By:believed,
estimated, /s/expected Luigior Brunintended. In each instance, forward-looking information
should be considered in light of the accompanying meaningful cautionary
statements herein.

Contact:

Tekron, Inc.
Mr. Luigi Brun,
Tel: President519-661-0509
Fax: 519-667-0366
Email: luigibrun@tekron-inc.com

3 Or
Dr. James Insell
Tel: 519-433-4400
Fax: 519-432-0535
Email: jpinsell@execulink.com

Source: Tekron, Inc.

Filing Compare · TEKRON INC